Peter Van Vlasselaer, PhD

US Investments
Peter Van Vlasselaer, PhD

Peter is a Venture Partner based in our San Francisco Bay Area office, focused on working with emerging clinical biotechnology companies. He has over 25 years of experience in the biotech industry, including CEO and/or Executive Chairman roles at SR One portfolio companies True North Therapeutics (acquired by Bioverativ, now part of Sanofi) and iPierian (acquired by BMS). Most recently, Peter was the Founder, President, and CEO of ARMO BioSciences (ARMO), a company he led through to its acquisition by Eli Lilly in 2018 for $1.6 billion, shortly after its IPO.

Prior to that, Peter founded and held CEO positions at Arresto Biosciences (acquired by Gilead) and Avidia (acquired by AMGEN). Prior to that, he held Executive positions at InterMune (ITMN) and Dendreon (DNDN). Peter and his respective teams have developed numerous products in clinical trials and he has been involved in the development of four FDA approved products, Provenge (prostate cancer), Actimmune (osteopetrosis), Esbriet (idiopathic pulmonary fibrosis) and Enjaymo (cold agglutinin) He currently serves on the Boards of Asceneuron where he is Chair, and Inspirna.

Peter has a degree in Zoology and a PhD in Immunology from the University of Leuven, Belgium. He was Postdoctoral Fellow at the Division of Rheumatology at the Stanford University Medical School and DNAX Research Institute. He has authored several peer-reviewed scientific publications and book chapters, and he is an inventor on multiple patents.

The challenge of translating novel science or technology into practice, and into therapies that matter to patients, is hugely motivating to me. Taking part in an industry that pushes the boundaries of science and technology is a privilege. As a member of the SR One team, I look forward to working with entrepreneurs that share this enthusiasm to help them realize their dreams.